IMV   $0.8225  -2.55% Market Closed

IMV Inc
Last Events:

2023-04-29 Signal in RSI changed from bullish recovery to bullish weakening. RSI indicator is in the upper part of the neutral territory and it heading south. These factors indicate that the downside trend is forming. Last signal: entrance to the overbought zone.

2023-04-28 Trend pattern changed from Not found to нисходящий треугольник.

2023-04-28 Signal in MACD changed from bullish reversal to bullish. Oscillator MACD is in the positive territory it's higher than the signal line and grows. These factors mean that positive mood prevails. Last signal: up-crossing the middle level.

2023-04-28 Signal in RSI changed from bearish recovery to bullish recovery. RSI indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: entrance to the overbought zone.

2023-04-28 Signal in EMA20 changed from bearish reversal to bullish reversal. 2023-04-17 the price crossed up the moving average line and demonstrates an upside trend.

2023-03-30 Trend pattern changed from канал to Not found.

2023-03-30 Signal in MACD changed from bearish recovery to bullish reversal. Oscillator MACD is in the negative territory it's higher than the signal line and grows. These factors mean that the falling period is over. Last signal: main and signal line crossing.

2023-03-29 Trend pattern changed from Not found to канал.


Current temperature: 0.97
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 3
Target Price Mean 38.33
Mean unverified/preliminary 38.33 / 38.33
Target Price Low / High 5.00 / 60.00
Median / STD DEV 50.00 / 29.30
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi Sell Sell Sell
macd - Sell -
stoch - Sell -
ma20 - Sell Sell
ma50 Sell - -
ma100 Sell Sell Sell
Candlestick PatternApril 28, 2023 Bearish Harami - consists of an unusually large white body followed by a small black body contained within. Large white body It is considered as a bearish pattern when preceded by an uptrend.
ISIN CA44974L1031
ceo Mr. Andrew Hall M.Sc.
Website https://www.imv-inc.com
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.